The Rising Tide of Social Activism in India Against Pharma Pricing & Practices “We are well aware that the decision to relinquish the patent on Trastuzumab is a tactical move by Roche to avoid compulsory licensing, which would have much more serious and far-reaching implications for its plans in the Indian market,” says Kalyani Menon-Sen, a feminist activist who also coordinates the Campaign for Affordable Trastuzumab (the chemical name for Herceptin) in India. Her comment reflects anticipation that Roche is expected to lobby the Indian government to strengthen guidelines for approving biosimilars. Although its patent may no longer be in force, Roche does not yet face competition for Herceptin, since there are currently no approved versions in India. pharmalive/a-preemptive-strike-roche-relinquishes-its-herceptin-patent-in-india
Posted on: Fri, 16 Aug 2013 02:39:26 +0000
Trending Topics
Recently Viewed Topics
© 2015